A Clinical Study of Intravenous Administration of RT-01 in Patients With Advanced Solid Tumors

  • End date
    Jun 1, 2023
  • participants needed
  • sponsor
    Wuxi People's Hospital
Updated on 24 November 2021


This is an open-label, dose escalation study of the safety and tolerability of oncolytic virus injection(RT-01) when administered via Intravenous injection in patients with advanced solid tumors.

The purpose of this study is to assess the safety and tolerability of RT-01 and to determine the recommended phase 2 dose (RP2D) for further study. The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of RT-01.


This is an investigator initiated , open-label, study of RT-01 given via intratumoral (IT) injection as a single agent and in combination with IV PD-1/PD-L1 in participants with advanced solid tumors.

The study consists of two partsIn the single agent dose escalation part (Part A), four doses (110^7 TCID50, 110^8 TCID50, 310^8 TCID50, 110^9 TCID50) of RT-01 will be delivered Intravenous as single agent to observe the DLTs and to identify the MTD. Part A is a single agent dose escalation which will use a 3+3 design to evaluate escalating doses of RT-01.

Once the IV RT-01 MTD is established, the Part B part of the study will begin. Part B is IV RT-01 in combination with IV PD-1/PD-L1 dose escalation which will use a 3+3 design to evaluate escalating doses of IV RT in combination with IV pembrolizumab.

Total enrollment will depend on the toxicities and/or activity observed, with approximately 16-36 evaluable participants enrolled.

The primary study objective is to determine the safety, tolerability, and maximum tolerated dose (MTD) of Intravenous administration of RT-01 as a single agent and in combination with immune checkpoint inhibitors. Secondary objectives will assess efficacy overall response rate, as well as disease control rate, progression free survival, duration of response, and anti-tumor immune responses.

Condition cancer advanced, Solid Tumor, Solid Tumour, Solid Neoplasm, Advanced Cancer, Solid Tumors
Treatment Oncolytic Virus Injection(RT-01), Oncolytic Virus Injection(RT-01)+pembrolizumab (PD-1)
Clinical Study IdentifierNCT05122572
SponsorWuxi People's Hospital
Last Modified on24 November 2021


Yes No Not Sure

Inclusion Criteria

Male or female aged 18 years
Subjects must have histologically- or cytologically-confirmed diagnosis of advanced solid tumor(s) and have progressed on or is not eligible for available standard therapy
Subjects have At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (non-nodal lesions with longest diameter 10 mm, or nodal lesions with short diameter 15 mm)
ECOG score of 0 ~ 2
Adequate bone marrow, hepatic and renal and coagulation function
Women of childbearing age who have a negative pregnancy test within 7 days before treatment. Female patients of childbearing age, and male patients with partners of childbearing age must agree to use at least one medically recognized contraceptive method during study treatment and within at least 6 months after the last dose of investigational drug
Voluntarily participated in this study, signed the informed consent form, had good compliance, and cooperated with the follow-up

Exclusion Criteria

Subjects with known brain metastasis and/or clinically history tumor brain of metastasis
Subjects who have received anti-tumor therapy such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, etc within 4 weeks
Subjects who have participate in another interventional study while receiving study IP within 4 weeks
Subjects who have had major surgery 4 weeks of dosing
Patients in any condition requiring systemic treatment with corticosteroids (prednisone > 10 mg/day or equivalent of the similar drug) or other immunosuppressive agents within 14 days prior to investigational drug administration, but currently or previously treated with any of the following steroid regimens, were included
Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption
Prophylactic short-term ( 7 days) use of corticosteroids (e.g., allergy to contrast media) or for the treatment of non-autoimmune diseases (e.g., delayed hypersensitivity caused by contact allergens)
Subjects received live vaccines within 7 days of initiation of study treatment
Subjects with adverse reactions caused by previous anti-tumor treatment not recovered to (CTCAE 5.0) grade 1 (except alopecia)
Subjects who have any active infection
Subjects with known positive history of human immunodeficiency virus (HIV) test or known acquired immunodeficiency syndrome (AIDS)
Subjects who have active hepatitis
Subjects who have serious cardiovascular system disorders history
Subjects with active autoimmune diseases or history of autoimmune diseases that may relapse
Subjects having any serious uncontrolled disease or in other conditions that would preclude them from receiving study treatment and are considered unsuitable for this study in the opinion of the investigator
Subjects in other conditions that are considered unsuitable for this study by the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note